Vion cancer news

Vion filed for Chapter 11 bankruptcy after receiving a complete response letter from the FDA for an NDA for Onrigin laromustine to treat acute myelogenous leukemia (AML). In the letter, the agency recommended another trial of the sulfonyl hydrazine DNA alkylating agent. The company had previously said that it does not have sufficient funds for a new randomized trial. ...